Blonanserin (BioDeep_00000176752)
human metabolite blood metabolite
代谢物信息卡片
2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
化学式: C23H30FN3 (367.2423632)
中文名称: 布南色林
谱图信息:
最多检出来源 Homo sapiens(blood) 98.67%
Reviewed
Last reviewed on 2024-09-14.
Cite this Page
Blonanserin. BioDeep Database v3. PANOMIX ltd, a top metabolomics service provider from China.
https://query.biodeep.cn/s/blonanserin (retrieved
2024-09-20) (BioDeep RN: BioDeep_00000176752). Licensed
under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
分子结构信息
SMILES: CCN1CCN(CC1)C1=NC2=C(CCCCCC2)C(=C1)C1=CC=C(F)C=C1
InChI: InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3
描述信息
C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist
Blonanserin (AD-5423) is a potent?and orally active 5-HT2A?(Ki=0.812 nM) and?dopamine D2?receptor?(Ki =0.142?nM)?antagonist. Blonanserin is usually acts as an atypical antipsychotic?agent and can be used for the research of extrapyramidal symptoms, excessive?sedation, or?hypotension[1].
同义名列表
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:31296
- PubChem: 125564
- HMDB: HMDB0249290
- DrugBank: DB09223
- ChEMBL: CHEMBL178803
- Wikipedia: Blonanserin
- chemspider: 111697
- CAS: 132810-10-7
- medchemexpress: HY-13575
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yoshiko Tomita, Takeshi Takagaki, Atsushi Kitamura, Erika Wada, Hironori Nishibe, Amane Tateno, Yoshiro Okubo. Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch.
Journal of clinical psychopharmacology.
2022 May; 42(3):260-269. doi:
10.1097/jcp.0000000000001545. [PMID: 35384896] - Shintaro Sakai, Yoshiro Morimoto, Yusuke Matsuzaka, Takeshi Nakano, Shinji Kanegae, Akira Imamura, Hiroki Ozawa. Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report.
Neuropsychopharmacology reports.
2021 09; 41(3):440-443. doi:
10.1002/npr2.12200. [PMID: 34357702] - Atsushi Kitamura, Takeshi Takagaki, Daisuke Nemoto, Yoshiko Tomita, Hironori Nishibe, Hiroyoshi Kakuyama. Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D2 Receptor Occupancy in Clinical Settings.
Journal of clinical pharmacology.
2021 08; 61(8):1069-1080. doi:
10.1002/jcph.1835. [PMID: 33599975] - Yukinori Akiyama, Kyoya Sakashita, Masayasu Arihara, Yusuke Kimura, Katsuya Komatsu, Takeshi Mikami, Nobuhiro Mikuni. COVID-19 infection in Hokkaido, Japan might depend on the viscosity of atmospheric air.
Virus research.
2021 02; 293(?):198259. doi:
10.1016/j.virusres.2020.198259. [PMID: 33309913] - Amalie Møller, Hayley B Schultz, Tahlia R Meola, Anette Müllertz, Clive A Prestidge. The Influence of Solidification on the in vitro Solubilisation of Blonanserin Loaded Supersaturated Lipid-Based Oral Formulations.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2021 Feb; 157(?):105640. doi:
10.1016/j.ejps.2020.105640. [PMID: 33189902] - Yoshifumi Inoue, Kimiko Tsuchimori, Hiroshi Nakamura. Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.
Journal of pharmacological sciences.
2021 Jan; 145(1):42-51. doi:
10.1016/j.jphs.2020.09.006. [PMID: 33357778] - Kengo Furuse, Wataru Ukai, Eri Hashimoto, Hanako Hashiguchi, Yoshiyasu Kigawa, Takao Ishii, Masaya Tayama, Kenta Deriha, Masaki Shiraishi, Chiaki Kawanishi. Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens.
Journal of affective disorders.
2019 03; 247(?):97-104. doi:
10.1016/j.jad.2019.01.007. [PMID: 30658246] - Tahnee J Dening, Nicky Thomas, Shasha Rao, Cis van Looveren, Filip Cuyckens, René Holm, Clive A Prestidge. Montmorillonite and Laponite Clay Materials for the Solidification of Lipid-Based Formulations for the Basic Drug Blonanserin: In Vitro and in Vivo Investigations.
Molecular pharmaceutics.
2018 09; 15(9):4148-4160. doi:
10.1021/acs.molpharmaceut.8b00555. [PMID: 30067372] - Amane Tateno, Takeshi Sakayori, Woo-Chan Kim, Kazuyoshi Honjo, Haruo Nakayama, Ryosuke Arakawa, Yoshiro Okubo. Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.
The international journal of neuropsychopharmacology.
2018 06; 21(6):522-527. doi:
10.1093/ijnp/pyy004. [PMID: 29346639] - Shuhua Deng, Xiaojia Ni, Dewei Shang, Zhanzhang Wang, Ming Zhang, Jinqing Hu, Xiuqing Zhu, Haoyang Lu, Yuqing Chen, Yuefeng Zhang, Huan Peng, Yuguan Wen. Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects.
Journal of clinical psychopharmacology.
2018 Apr; 38(2):129-133. doi:
10.1097/jcp.0000000000000851. [PMID: 29424805] - De-Wei Shang, Zhan-Zhang Wang, Hai-Tang Hu, Yue-Feng Zhang, Xiao-Jia Ni, Hao-Yang Lu, Ming Zhang, Jin-Qing Hu, Chang Qiu, Huan Peng, Ling-Fang Shen, Yu-Guan Wen. Effects of food and grapefruit juice on single-dose pharmacokinetics of blonanserin in healthy Chinese subjects.
European journal of clinical pharmacology.
2018 Jan; 74(1):61-67. doi:
10.1007/s00228-017-2340-1. [PMID: 28975417] - Tomomi Tsubai, Akira Yoshimi, Yoji Hamada, Makoto Nakao, Hiroshi Arima, Yutaka Oiso, Yukihiro Noda. Effects of clozapine on adipokine secretions/productions and lipid droplets in 3T3-L1 adipocytes.
Journal of pharmacological sciences.
2017 Feb; 133(2):79-87. doi:
10.1016/j.jphs.2017.01.004. [PMID: 28209485] - Huafang Li, Chen Yao, Jianguo Shi, Fude Yang, Shuguang Qi, Lili Wang, Honggeng Zhang, Jie Li, Chuanyue Wang, Chuansheng Wang, Cui Liu, Lehua Li, Qiang Wang, Keqing Li, Xiaoyan Luo, Niufan Gu. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
Journal of psychiatric research.
2015 Oct; 69(?):102-9. doi:
10.1016/j.jpsychires.2015.07.015. [PMID: 26343601] - Itaru Miura, Tetsuya Shiga, Akihiko Katsumi, Keiko Kanno-Nozaki, Hirobumi Mashiko, Shin-Ichi Niwa, Hirooki Yabe. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Human psychopharmacology.
2014 Mar; 29(2):199-202. doi:
10.1002/hup.2386. [PMID: 24590545] - Xia Chen, Hongyun Wang, Ji Jiang, Rui Chen, Ying Zhou, Wen Zhong, Hongzhong Liu, Pei Hu. The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses.
Clinical drug investigation.
2014 Mar; 34(3):213-22. doi:
10.1007/s40261-013-0167-9. [PMID: 24399453] - Taro Kishi, Yuki Matsuda, Nakao Iwata. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
PloS one.
2014; 9(2):e88049. doi:
10.1371/journal.pone.0088049. [PMID: 24505373] - Ying Zhou, Ming Liu, Ji Jiang, Hongyun Wang, Pei Hu. Simultaneous determination of blonanserin and its four metabolites in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2013 Nov; 939(?):59-66. doi:
10.1016/j.jchromb.2013.09.007. [PMID: 24099858] - Kentaro Kawabe, Fumie Horiuchi, Shu-ichi Ueno. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
Clinical neuropharmacology.
2013 Nov; 36(6):239-41. doi:
10.1097/wnf.0000000000000006. [PMID: 24201238] - Amane Tateno, Ryosuke Arakawa, Masaki Okumura, Hajime Fukuta, Kazuyoshi Honjo, Keiichi Ishihara, Hiroshi Nakamura, Shin-ichiro Kumita, Yoshiro Okubo. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Journal of clinical psychopharmacology.
2013 Apr; 33(2):162-9. doi:
10.1097/jcp.0b013e3182825bce. [PMID: 23422369] - Yu-Guan Wen, De-Wei Shang, He-Zhi Xie, Xi-Pei Wang, Xiao-Jia Ni, Ming Zhang, Wei Lu, Chang Qiu, Xia Liu, Fang-Fang Li, Xuan Li, Fu-Tian Luo. Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake.
Human psychopharmacology.
2013 Mar; 28(2):134-41. doi:
10.1002/hup.2290. [PMID: 23417765] - Tomoko Inoue, Kenichi Osada, Masaaki Tagawa, Yuriko Ogawa, Toshiaki Haga, Yoshihisa Sogame, Takanori Hashizume, Takashi Watanabe, Atsushi Taguchi, Takashi Katsumata, Masashi Yabuki, Noboru Yamaguchi. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
Progress in neuro-psychopharmacology & biological psychiatry.
2012 Oct; 39(1):156-62. doi:
10.1016/j.pnpbp.2012.06.005. [PMID: 22691713] - Yu-Guan Wen, Xiao-Jia Ni, Ming Zhang, Xia Liu, De-Wei Shang. Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Aug; 903(?):46-52. doi:
10.1016/j.jchromb.2012.06.037. [PMID: 22818206] - Hidenobu Suzuki, Keishi Gen. The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT(2A) activity/anti-dopamine D₂ activity ratio and drug-induced extrapyramidal symptoms.
Psychiatry and clinical neurosciences.
2012 Mar; 66(2):146-52. doi:
10.1111/j.1440-1819.2011.02311.x. [PMID: 22353327] - Junji Saruwatari, Norio Yasui-Furukori, Yoshimasa Inoue, Sunao Kaneko. Effect of dose timing in relation to food intake on systemic exposure to blonanserin.
European journal of clinical pharmacology.
2010 Sep; 66(9):899-902. doi:
10.1007/s00228-010-0834-1. [PMID: 20490472] - Hidenobu Suzuki, Keishi Gen. The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity.
Human psychopharmacology.
2010 Jun; 25(4):342-6. doi:
10.1002/hup.1124. [PMID: 20521325] - Tadashi Ogawa, Hideki Hattori, Rina Kaneko, Kenjiro Ito, Masayo Iwai, Yoko Mizutani, Tetsuya Arinobu, Akira Ishii, Osamu Suzuki, Hiroshi Seno. Sensitive analysis of blonanserin, a novel antipsychotic agent, in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.
2010; 26(10):1099-102. doi:
10.2116/analsci.26.1099. [PMID: 20953055] - M Matsuda, M Sakashita, T Yamaguchi, T Fujii. Determination of a novel anti-psychotic agent AD-5423 and its metabolites in plasma by high-performance liquid chromatography with fluorescence detection.
Journal of pharmaceutical and biomedical analysis.
1997 Jun; 15(9-10):1449-56. doi:
10.1016/s0731-7085(96)02037-7. [PMID: 9226575] - L Giuliani, G Carmignani, E Belgrano, P Puppo. Transcatheter arterial embolization in urological tumors: the use of isobutyl-2-cyanoacrylate.
The Journal of urology.
1979 May; 121(5):630-4. doi:
10.1016/s0022-5347(17)56913-x. [PMID: 439260]